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The term dilated cardiomyopathy (DCM) defines a heterogeneous group of cardiac disorders, which are characterized by left ventricular
or biventricular dilatation and systolic dysfunction in the absence of abnormal loading conditions or coronary artery disease sufficient to
cause global systolic impairment. In approximately one third of cases, DCM is familial with a genetic pathogenesis and various patterns of
inheritance. Although the electrocardiogram (ECG) has been considered traditionally non-specific in DCM, the recently acquired knowledge
of the genotype–phenotype correlations provides novel opportunities to identify patterns and abnormalities that may point toward specific
DCM subtypes. A learned ECG interpretation in combination with an appropriate use of other ECG-based techniques including ambulatory
ECG monitoring, exercise tolerance test and imaging modalities, such as echocardiography and cardiovascular magnetic resonance, may
allow the early identification of specific genetic or acquired forms of DCM. Furthermore, ECG abnormalities may reflect the severity of the
disease and provide a useful tool in risk stratification and management. In the present review, we discuss the current role of the ECG in
the diagnosis and management of DCM. We describe various clinical settings where the appropriate use and interpretation of the ECG can
provide invaluable clues, contributing to the important role of this basic tool as cardiovascular medicine evolves.
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Introduction
Dilated cardiomyopathy (DCM) is currently defined by the pres-
ence of left ventricular (LV) or biventricular dilatation and systolic
dysfunction in the absence of abnormal loading conditions or coro-
nary artery disease sufficient to cause global systolic impairment.1
Dilated cardiomyopathy is an umbrella definition that encompasses
multiple disorders where myocardial abnormality is not related to
coronary or valvular or congenital heart disease and cannot be
explained by abnormal haemodynamic conditions.2 Besides being
very generic, the term DCM may be downright inaccurate, as
chamber dilatation is often absent: indeed, the term ‘dilated’ has
recently been questioned. This nosographic complexity builds on a
significant genetic heterogeneity with mutations found to be linked
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. to the disease in at least 50 different individual genes and a polymor-
phic clinical presentation with arrhythmias and heart failure being
the most common manifestation.1
Recent technological advances in cardiovascular imaging, partic-
ularly the increasingly widespread use of cardiovascular magnetic
resonance (CMR), offer an opportunity for deep phenotypic and
aetiological definition through tissue characterization, allowing the
identification of among others oedema, fibrosis, or infiltration.
Yet, in this complex landscape full of rapidly developing diagnostic
technologies, the electrocardiogram (ECG) retains an extremely
powerful role in the assessment of patients with DCM, which can
provide diagnostic red flags useful to orient the following phases of
the diagnostic work-up, prognostic stratification criteria and infor-
mation that can direct appropriate decision making.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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In this review, we will discuss the several reasons why the
ECG is still a paramount piece of the puzzle in diagnosis, risk
stratification and management of DCM. Following an overview
of abnormalities involving each segment of the ECG, individ-
ual diseases characterized by specific patterns are discussed in
detail.
Methods
The authors approached the topic formulating the research question:
what is the role of ECG in diagnosis and management of DCM? There-
fore a systematic search through the web-based engine PubMed was
conducted in order to identify all studies meeting the eligibility crite-
ria. The most relevant studies answering the main research question
were selected. Finally, results were presented systematically taking into
account the complexity of the disease and the various aetiologic back-
grounds.
Systematic approach in ECG
interpretation
Electrocardiographic abnormalities characterize the majority of
patients with DCM, with abnormal ECG features reported in more
than 80% of the cases (Table 1).3–10 Despite the traditional opinion
that ECG abnormalities in DCM are non-specific, in contrast with
other cardiomyopathies, such as hypertrophic cardiomyopathy (HCM)
or arrhythmogenic right ventricular cardiomyopathy (ARVC), recent
advances in the understanding of genotype–phenotype correlations
provide the opportunity to recognize specific ECG patterns that
are typical of certain genetic or acquired forms of DCM.5 As the
ECG is rarely normal in DCM, ECG abnormalities should trigger
the initiation of a diagnostic work-up. However, when interpreting
the ECG of patients with cardiomyopathies, the approach should be
‘cardiomyopathy-oriented’, i.e. abandoning classical concepts derived
from the world of ischaemic and hypertensive heart disease, and
focusing on specific ‘red flags’ (Table 2)1,11–19 that should be carefully
integrated in the broader clinical and familial context.
P wave
Atria are often dilated in DCM, reflecting raised filling pressures and/or
associated valvular abnormalities. This may be reflected on the ECG
with P-wave changes suggestive of left and/or atrial enlargement.20
While isolated right atrial enlargement is uncommon,3,5,6 left atrial
enlargement is seen in a variable proportion of patients and is often
considered a marker of long-standing disease.3,5–7 Atrial fibrillation
(AF) is a common pathway for all forms of DCM following progression
to heart failure. Early onset of AF in young individuals, however, may
suggest specific DCM aetiologies, mainly of genetic origin12 (Table 2).
PR interval
First-degree and/or advanced atrio-ventricular (AV) blocks can be
found in patients with DCM1; conduction abnormalities, especially in
young patients, suggest a specific genetic background often associated
with neuromuscular diseases, laminopathy, or ion channel disorder.
Conduction abnormalities are also relatively common in acquired
conditions such as cardiac sarcoidosis and Chagas disease.21 ..
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Table 1 Main electrocardiographic features in dilated
cardiomyopathy
ECG feature No. Males
(%)
Mean
LVEF
(%)
Prevalence
(%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LVHa 17–69
Roberts et al., 19873 152 72 – 39
Momiyama et al., 19944 45 – – 69
Merlo et al., 20195 414 71 32 17
LA enlargement 17–51
Roberts et al., 19873 152 72 – 35
Wilensky et al., 19886 56 82 – 51
Kamiyama et al., 19977 41 71 – 51
Merlo et al., 20195 414 71 32 17
LBBB 23–28
Grimm et al., 20038 343 78 31 28
Merlo et al., 20195 414 71 32 23
Abnormal Q waves 26–36
Wilensky et al., 19886 56 82 – 36
Merlo et al., 20195 414 71 32 26
AF 3–25
Roberts et al., 19873 152 72 – 25
Wilensky et al., 19886 56 82 – 14
Aleksova et al., 20109 539 73 30 10
Merlo et al., 20195 414 71 32 3
First degree AV block 10–23
Hamby et al., 186810 60 – – 18
Roberts et al., 19873 152 72 – 23
Merlo et al., 20195 414 71 32 10
Inferior T-wave inversion
Merlo et al., 20195 414 71 32 14
Anterolateral T-wave
inversion
Merlo et al., 20195 414 71 32 13
RBBB 2–6
Roberts et al., 19873 152 72 – 6
Wilensky et al., 19886 56 82 – 6
Merlo et al., 20195 414 71 32 2
RA enlargement 3–6
Roberts et al., 19873 152 72 – 6
Wilensky et al., 19886 56 82 – 3
Merlo et al., 20195 414 71 32 4
AF, atrial fibrillation; AV, atrio-ventricular; LA, left atrial; LBBB, left bundle branch
block; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy;
RA, right atrial; RBBB, right bundle branch block.
aBased on Sokolow–Lyon or Cornell voltage criteria.
QRS complex
Loss of vital myocardium and diffuse LV fibrosis may both lead to
reduced QRS amplitude, especially in the precordial leads.3,5,10 Low
QRS voltages may also reflect fat infiltration, such as in arrhythmogenic
cardiomyopathy due to desmosomal gene mutations, with involvement
of the left as well as the right ventricle.21,22 When LV hypertrophy
(LVH) voltage criteria (either Sokolow–Lyon or Cornell) are met in
patients with DCM, a hypertensive aetiology should be excluded.3–5
Left bundle branch block (LBBB) is found in roughly one third of
patients with DCM,23 sometimes preceding the structural phenotype,
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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and carries an adverse prognostic value; LBBB can be the result of
a discrete lesion within the his bundle, as suggested by Narula24
explaining why pacing at the distal His bundle can improve electrical end
echocardiographic desynchronization in patients with LBBB.25 Many
patients with a diagnosis of LBBB have a combination of LVH and left
anterior fascicular block rather than true LBBB.26 True LBBB should
be diagnosed if QRS duration is ≥140ms (130ms in women), there is
a QS or rS pattern in V1-V2 and mid-QRS notching or slurring in ≥2
of leads V1, V2, V5, V6, I, aVL. After cardiac resynchronization therapy
(CRT), this morphology is associated with a better echocardiographic
response and survival than other intraventricular delays.27
Right bundle branch block (RBBB) is generally uncommon in patients
with DCM (2–6%)3,5,6 but it is frequently found in patients with
neuromuscular disease due to pathogenic variants in the dystrophin
gene.28
Q waves
The lack of consensus regarding the definition of a pathological Q wave,
with multiple proposed diagnostic criteria, constitutes a source of
confusion. Q-wave duration≥40ms or an absolute depth of>3mm are
considered pathological criteria by some, whereas others recommend
an amplitude ≥25% of the ensuing R wave.20 Q waves may be observed
in DCM in the absence of ischaemic heart disease and are more
common in the anterior and lateral leads.5,6 As discussed below,
cardiac involvement in muscular dystrophies is often characterized by
posterior or inferior Q waves, which reflect transmural myocardial
fibrosis.29
ST segment/T-wave abnormalities
Repolarization abnormalities are common in DCM, and generally
reflect LV impairment. T-wave inversion (TWI), especially in the lateral
leads, is a recognized feature of certain genetic forms (for example
filamin C or desmosomal disease).13 In contrast to HCM, where
striking repolarization abnormalities (such as deep TWI especially in
the lateral leads) are common, TWI in DCM is less deep and not
associated with voltage criteria for LVH.14,30
QT interval
The QTc interval is generally normal in DCM. A short QT interval
has been associated with primary carnitine deficiency which may cause
DCM.31 QT variability at prolonged monitoring has been shown to
be of potential use in sudden cardiac death (SCD) risk stratification in
patients with DCM.32
Ventricular premature beats
Ventricular premature beats (VPBs) may be found in up to 40%
of patients with DCM.33 Frequent VPBs may promote LV systolic
dysfunction and in some cases it may be challenging to establish
whether VPBs are the main driving force of LV systolic dysfunction
(tachycardiomyopathy), an arrhythmic manifestation of an underlying
cardiomyopathy, or an innocent by-stander. There is no consensus
regarding the burden of VPBs considered to be sufficient to cause LV
systolic dysfunction; however, a high burden has been variably defined
as ranging from >10 000 to 25 000 VPBs/day and as >10% to 24%
of total heart-beats during the 24 h.19 The type and not only the
burden of VPBs is relevant in the differential diagnosis between forms of
DCM. Moreover, certain VPBs morphologies are commonly identified ..
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.. in athletes and are considered benign. These include infundibular and
fascicular morphologies. On the contrary, other morphologies of VPBs
such as LBBB/intermediate or superior axis or RBBB/intermediate or
superior axis and wide QRS may be a sign of underlying myocardial
disease.34
An ‘arrhythmogenic’ subset of genetic DCM, epitomized by lamin
A/C and desmosomal forms of DCM, is characterized by complex and
polymorphic ventricular arrhythmias (including frequent VPBs) early
in the course of the disease, heralding increased risk of SCD.12 The
presence of VPBs and/or non-sustained ventricular tachycardia (NSVT)
does not generally dictate the choice of protecting a patient with
DCM phenotype with an implantable cardioverter-defibrillator (ICD)
in primary prevention. However, the presence of frequent arrhythmias,
especially if associated with pathogenic variants in desmosomal genes
and/or myocardial fibrosis at CMR, may suggest a high risk of SCD and
therefore an ICD should be considered in this setting.
The development of ventricular arrhythmias at the exercise toler-
ance test, including an increase in VBPs or development of NSVT during
exercise, may be a sign of an arrhythmogenic phenotype with underly-
ing desmosomal pathogenic variants.1
Supraventricular arrhythmias
The identification of AF through ambulatory monitoring is an impor-
tant aspect of management of DCM and may dictate important choices
as commencement of anticoagulation therapy for stroke prevention.1
The detection of paroxysmal supraventricular arrhythmias in young
patients with DCM should prompt investigation for familial LMNA
cardiomyopathy.12
In summary, from a practical standpoint, when approaching a patient
with unexplained LV dilatation and/or systolic dysfunction, a systematic
analysis of the ECG from the beginning of the P wave to the end of the T
wave may provide invaluable clues that may point toward the diagnosis
of specific subtypes with implications for management and prognosis.
The ECG in specific genetic forms
of dilated cardiomyopathy
Some ECG features are clues of specific genetic DCM subtypes, as
certain disease-causing genes are associated with characteristic ECG
abnormalities35 (Table 2 and Figure 1) that may have diagnostic as well
as prognostic value for the patients and their relatives. For example,
pathogenic variants in certain genes (lamin A/C, filamin C, desmosomal
genes and phospholamban) may express an arrhythmogenic phenotype,
which should lead to early decisions on ICD implantation in primary
prevention. In the following lines, we describe ECG patterns in some
of the most common DCM-associated genotypes.
Titin
Truncating variants in the gene for the sarcomeric protein titin (TTN)
have been identified as the most common genetic cause of DCM and
found in 10% to 20% of cases.36 A typical ECG pattern of patients
harbouring pathogenic variants in TTN has not been described. A
recent study37 on one of the largest cohorts to date, showed that
patients with TTN truncating variants had a higher prevalence of AF
and ventricular arrhythmias than DCM patients with other aetiologies,
while the prevalence of LBBB and conduction abnormalities was lower.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
4 G. Finocchiaro et al.
Figure 1 Electrocardiograms of dilated cardiomyopathy patients with underlying pathogenic variants. (A) First degree atrio-ventricular block
and right bundle branch block with left anterior hemiblock in a carrier of an LMNA pathogenic variant. (B) Low voltages in the limb leads and
inferolateral T-wave inversion in a carrier of an FLNC pathogenic variant. (C) Inferolateral pseudo-necrosis in a carrier of a DMD pathogenic
variant. (D) First-degree atrio-ventricular block and frequent ventricular premature beats in a carrier of an SCN5A pathogenic variant.
Lamin A/C
Variants of the lamin A/C gene (LMNA) are found in up to 8% of DCM
cases.38 Early conduction disease, manifesting as sinus bradycardia,
sinus node arrest, AV blocks (first or second degree AV block, later
progressing to complete heart block) or LBBB are relatively common
in this form of DCM.1 Such findings often precede the development of
an overt dilated phenotype (Figure 1A). These patients exhibit a high
prevalence of supraventricular arrhythmias, in particular AF (present
in almost half of the patients at their first presentation), but also atrial
flutter and atrial tachycardia.39 Frequent VPBs and episodes of NSVT
may also be found at the ECG or at ambulatory monitoring. Risk of
SCD and progression to refractory heart failure is common in this
genetic subset.
Similar to the LMNA variants, variants in the emerin gene (EMD
or STA), responsible for Emery–Dreifuss muscular dystrophy, fre-
quently lead to conduction disturbances40 and supraventricular
arrhythmias.41
Filamin C
Filamin C is an intermediate filament that cross-links polymerized
actin, contributing to anchoring cellular membrane proteins to the
cytoskeleton. Filamin C gene (FLNC) variants account for about 4%
of DCM cases.13,16,38 Repolarization abnormalities, especially TWI in
the precordial or inferolateral leads are a common finding in patients
with FLNC variants.14 Approximately 25% of carriers show low voltages .
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.. in the limb leads14 (Figure 1B) and frequent VPBs and NSVT are
common.14
Dystrophin
The dystrophin gene (DMD) is located on the short arm of the X
chromosome and shows an X-linked pattern of inheritance. Cardiac
involvement is present in approximately 90% of the cases of Duchenne’s
muscular dystrophy and 70% of Becker’s muscular dystrophy.1 The
ECG in DCM due to DMD pathogenic variants classically mimics a
posterior, inferior and/or lateral myocardial infarction, with abnormal
Q waves in leads I, aVL and V6 or in leads II, III and aVF, associated with
high-voltage R waves in leads V1 and V2, which is due to the progressive
accumulation of a transmural scar in the posterolateral region of the
left ventricle42 (Figure 1C). Short PR interval and sinus tachycardia are
also frequent, along with right-axis deviation and RBBB.43
Desmin
Desmin is a cytoskeletal protein which forms muscle-specific interme-
diate filaments.
Pathogenic variants in the gene encoding desmin (DES) cause a
wide spectrum of phenotypes of different cardiomyopathies, skeletal
myopathies, and mixed skeletal and cardiac myopathies. Desmin vari-
ants account for 1–2% of all cases of DCM.1 ECG abnormalities are
common in this setting (up to 60% of the cases).44 Conduction abnor-
malities are frequently observed (AV blocks and RBBB), followed by
supraventricular and ventricular arrhythmias.44
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Electrocardiographic ‘red flags’ for genetic
forms of dilated cardiomyopathy
Red flag Gene Reported
prevalence
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sinus node disease1,11
Sinus bradycardia or sinus node arrest LMNA 13%
SCN5A –
AV block (various degree) LMNA 45–77%
EMD –
DES –
SCN5A –
Conduction system disease11,12
Short PR interval DMD 35%
RBBB DMD –
DES –
Depolarization abnormalities13–15
Low voltages FLNC 36%
DSP –
PLN 46%
Inferolateral Q waves DMD 13%
Repolarization abnormalities16,17
T-wave inversion FLNC 62%
DSP –
Supraventricular arrhythmias1,18
AF LMNA 36–76%a
EMD –
DES –
SCN5A –
Atrial flutter LMNA –
EMD –
Atrial tachycardia LMNA –
EMD –
Sinus tachycardia DMD –
Ventricular arrhythmias11,13,14,16,19
Frequent VPBs LMNA –
FLNC 70%
DES –
DSP –
SCN5A –
NSVT LMNA 37%
FLNC 83%
DES –
DSP –
SCN5A –
AF, atrial fibrillation; AV, atrio-ventricular; DES, desmin; DMD, dystrophin;
DSP, desmoplakin; EMD, emerin; FLNC, filamin C; LMNA, lamin A/C; NSVT,
non-sustained ventricular tachycardia; PLN, phospholamban; RBBB, right bundle
branch block; SCN5A, cardiac sodium channel type 5 𝛼-subunit; VPB, ventricular
premature beat.
aThe number refers to the prevalence of any supraventricular arrhythmia.
Cardiac sodium channel type 5 𝜶-subunit
Cardiac sodium channel type 5 𝛼-subunit (SCN5A) encodes the major
sodium channel expressed in the heart. Variants in SCN5A gene
have been associated with primary arrhythmia syndromes, including
the long QT and Brugada syndromes and missense variants have
been described also in familial DCM. SCN5A variants lead to various ..
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.. phenotypical expressions, including isolated conduction defects, NSVT
and familial, early-onset AF, which may be associated with LV systolic
dysfunction11,45 (Figure 1D).
Desmosomal genes
Although desmosomal variants have been historically associated with
ARVC, recent studies have shown that ARVC is often characterized
by LV involvement with forms that are phenotypically very similar to
DCM.13,21 A recent study reported desmosomal genes pathogenic vari-
ants in 3.5% of patients with DCM.13 The ECG in patients harbouring
variants in desmosomal genes may be characterized by low voltages
on both limb and precordial leads, delayed ventricular depolarization
and repolarization abnormalities including TWI that may extend to the
lateral leads (V5–V6)46 (Figure 2). Low voltages are due to the typical
subepicardial distribution of fibrofatty replacement within the left ven-
tricle, often circumferential, preventing electrical transmission from the
inner layers. Patients with DCM harbouring desmosome gene variants
often develop ventricular arrhythmias and are at risk of SCD.13
RNA-binding motif 20
RNA-binding motif 20 (RBM20) is an RNA-binding protein expressed
highly in both atria and ventricles involved in alternative splicing
process. DCM in RBM20 variants is frequently associated with early
onset, severe heart failure, and arrhythmic potential.1 Although RBM20
mouse models showed a prolonged PR and heart rate-corrected QT
interval, these features are not exhibited in humans and a typical ECG
pattern has not been described. A genetic diagnosis is important as
a distinct propensity to sustained ventricular arrhythmias has been
observed in patients harbouring RBM20 variants.47
Phospholamban
The PLN gene encodes phospholamban, a protein responsible for inhi-
bition of sarco−/endoplasmic reticulum Ca2+-ATPase (SERCA) func-
tion. Variants in the PLN gene result in increased SERCA inhibition
with defective calcium reuptake, with consequent reduction in con-
tractility and DCM phenotypic expression. In some DCM cohorts,
especially in The Netherlands and in Germany (due to founder muta-
tions), the prevalence of PLN variants is high. Typical ECG features are
low QRS complex potentials and decreased R-wave amplitude, mainly
in anterior-lateral precordial leads.15
In summary, the genetic background of DCM may be complex and
the ECGmay suggest specific genetic abnormalities. ECG ‘red flags’ may
indeed point toward particularly aggressive genetic forms that would
require specific management, such as ICD implantation in primary
prevention at an early stage of the disease.
The ECG in other cardiomyopathies
with dilated hypokinetic phenotype
Left ventricular or biventricular dilatation and systolic dysfunction is a
common final result of various disease processes. Cardiomyopathies
characterized by myocardial infiltration or by LVH at an initial stage
may progress toward LV dilatation and dysfunction. Typically, cardiac
amyloidosis (especially the AL form) may be characterized by significant
reduction of QRS voltages, a feature that may be shared also by HCM
in the so-called ‘burn-out’ phase. While this ECG sign reflects an
infiltrative myocardial process in cardiac amyloidosis, it underlies high
myocardial fibrosis burden in HCM.30
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Electrocardiogram of a 32-year-old woman exhibiting a dilated cardiomyopathy phenotype, found to have a desmoplakin pathogenic
variant. Note the low voltages on the limb and precordial leads. Cardiovascular magnetic resonance (late gadolinium enhancement sequences)
shows subepicardial late gadolinium enhancement, which is more evident at the level of the right side of the interventricular septum and the
basal lateral wall.
The ECG in non-genetic forms of dilated
cardiomyopathy
A number of chemical compounds can induce DCM, the most common
of which are chemotherapeutic agents, cocaine and alcohol. Inflam-
mation and auto-immune response can result in particularly malignant
forms of DCM.23 Some ECG features are typical of specific acquired
forms of DCM (Table 3).
Inflammatory cardiomyopathies
Acute myocarditis may result in chronic inflammation and evolution
to DCM in a variable proportion of patients.48 The spectrum of ECG
features in DCM resulting from previous myocarditis is wide and often
non-specific. However, especially in the acute inflammatory phase,
low voltages (reflecting concomitant pericardial effusion or myocardial .
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. fibrosis), conduction abnormalities (especially in myocarditis due to
Lyme disease), lateral TWI, increased QRS duration and frequent
VPBs or NSVT might be present28 (Figure 3A). A specific form of
inflammatory cardiomyopathy is Chagas disease, caused by the parasite
Trypanosoma cruzi and common in South America and Central America.
Chagas disease is characterized by conduction system abnormalities,
most commonly RBBB with left anterior fascicular block and AV
blocks.49
A clinically manifest cardiac involvement with LV or biventricular
systolic dysfunction with or without chamber enlargement occurs in
approximately 5% of patients affected by systemic sarcoidosis, but a
silent disease is far more common, according to autopsy studies.50
The most common ECG manifestations are abnormalities in the
conduction system, such as AV blocks, bundle branch blocks and
fascicular blocks51,52 (Figure 3B). Unexplained advanced AV blocks in
young individuals, especially if associated with LV systolic dysfunction,
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Non-genetic forms of dilated cardiomyopathy
and electrocardiographic features
• Post-inflammatory
DCM
- Low voltages
- T-wave inversion (especially in the
lateral leads)
- Prolonged QRS duration
- Frequent VPBs and NSVT
- RBBB and LAH or high-degree AV
blocks (Chagas disease)
• Cardiac sarcoidosis - High-degree AV blocks
- RBBB
- Frequent VPBs and NSVT
• Tachycardia-induced
DCM
- AF
- Frequent VPBs
• Chemotherapy-
induced DCM
- Non-specific findings (low QRS
voltages and prolonged QTc correlate
with disease prognosis)
• Toxic-induced DCM - Non-specific findings (LBBB, various
degree AV blocks, non-specific
ST-segment alterations)
AF, atrial fibrillation; AV, atrio-ventricular; DCM, dilated cardiomyopathy; LAH,
left anterior hemiblock; LBBB, left bundle branch block; NSVT, non-sustained
ventricular tachycardia; RBBB, right bundle branch block; VPB, ventricular pre-
mature beat.
should raise the suspicion of cardiac sarcoidosis.53 Frequent VPBs and
non-sustained or sustained ventricular tachycardia are also common,
and might be the first presentations of the disease.54
Tachycardia-induced cardiomyopathy
Tachycardia-induced cardiomyopathy is defined as the reversible
impairment of ventricular function with or without chamber dilata-
tion induced by persistent arrhythmia.23 Both atrial and ventricular
arrhythmias may cause or at least promote LV or biventricular systolic
dysfunction. The exclusion of underlying structural heart disease may
be challenging as current imaging techniques, for example CMR, cannot
easily identify diffuse fibrosis which may be a substrate for arrhythmias.
In this setting, the ECG (and prolonged ECG monitoring) may provide
useful insights in the diagnosis (Figure 3C). For example the demonstra-
tion of high VPBs burden or of atrial arrhythmias, especially if poorly
controlled in terms of heart rate, may suggest tachycardia-induced
cardiomyopathy where a timely diagnosis is important given the
potential for recovery with appropriate treatment.19
Dilated cardiomyopathy caused by drugs and toxins
A series of drugs and toxins can cause DCM. Anthracyclines and
several other agents used for oncologic treatment may be toxic for
the heart, resulting in a clinical picture that is generally characterized
by LV systolic dysfunction with or without LV dilatation, often without
a specific ECG pattern. Prolonged QTc interval and decreased QRS
voltages have been shown to correlate with LV systolic dysfunction in
this setting55 (Figure 3D). The burden of arrhythmia in patients with
anthracycline-related cardiomyopathy is not different from patients
with other forms of DCM.56
The relationship between alcohol intake and heart failure is influ-
enced by various genetic and environmental factors. The diagnosis
of alcoholic DCM is based on a history of heavy alcohol intake ..
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.. (>80–100 g/day for >10 years) in combination with otherwise
unexplained cardiomyopathy.57 Non-specific abnormalities like com-
plete or incomplete LBBB, AV conduction disturbances, alterations
in the ST segment can be found comparable to those of idiopathic
DCM.58
Cocaine and methamphetamines are sympathomimetic drugs that
induce heightened inotropic and chronotropic effects. The effects on
the heart are multiple, including coronary vasospasm, atherosclero-
sis and LV systolic dysfunction. Although in the acute setting ECG
ischaemic changes are often present, specific ECG patterns are often
absent in the chronic phase.
Differential diagnosis with cardiac
adaptation to exercise
Long-term athletic training is associated with a series of alterations in
cardiac structure, function and electrical activity and chamber dilatation
is commonly observed especially in endurance athletes.59 Significant
LV dilatation in athletes may pose a challenge in the differential
diagnosis with DCM. Recent international recommendations for ECG
interpretation in athletes underscore which abnormalities should be
considered as reflective of physiological adaptation to exercise and
which instead should be regarded as highly suggestive of pathology.20
While isolated voltage criteria for LVH or left-axis deviation are highly
suggestive of a normal process, low voltages, LBBB, repolarization
abnormalities and pathological Q waves are more likely expression of
DCM. Although sinus bradycardia and first-degree AV block are normal
findings in athletes, extreme bradycardia (< 30 bpm) and advanced AV
blocks suggest a pathologic process and should be further investigated.
In summary, unexplained dilatation and/or systolic dysfunction is a
description of a phenotype, but not a diagnosis. Although DCM may
be genetic/familial in up to 25% of cases,1 secondary causes should be
excluded. In this context, a correct ECG interpretation in conjunction
with a detailed personal and family history may provide useful clues
for the final diagnosis. A correct identification of a possible secondary
process underlying LV systolic dysfunction is relevant as, in some cases,
LV systolic dysfunction may be reversible after specific treatment.
Standard ECG for risk stratification
Dilated cardiomyopathy is a dynamic condition and ECG abnormalities
reflect the natural history of the disease. The presence of LBBB at
baseline has been reported as an independent predictor of worse
outcomes (all-cause mortality and SCD) in patients with severely
impaired systolic function.60 Moreover, a significant proportion of
patients develop new-onset LBBB during follow-up, which likewise is a
strong and independent predictor of all-cause mortality.61 Selection of
patients who may potentially benefit from CRT is based on the severity
of their LV systolic dysfunction, of their symptoms [as assessed by
New York Heart Association (NYHA) class], and most importantly,
ECG criteria indicative of ventricular dyssynchrony.2,62 In general
terms, current European and American guidelines recommend CRT in
symptomatic heart failure patients (NYHA class ≥II) with an ejection
fraction of ≤35%,63 LBBB, and a QRS duration of ≥150ms.64,65
Although patients with LBBB are more likely to respond to CRT
compared to patients with RBBB or non-specific interventricular
conduction delay,66 both these guidelines also state that CRT should
be considered in non-LBBB with QRS ≥150ms. American guidelines
widen their indication for CRT to include patients with ischaemic
cardiomyopathy and NYHA class I symptoms with an ejection fraction
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Non-genetic forms of dilated cardiomyopathy. (A) Diffuse low amplitude of the QRS complexes, prolonged QRS duration and
lateral T-wave inversion in a patient with post-myocarditis dilated cardiomyopathy. (B) First-degree atrio-ventricular block and complete right
bundle branch block in a patient with cardiac sarcoidosis and frequent premature ventricular contractions. (C) Frequent fascicular ventricular
premature beats in a patient with tachycardia-induced-cardiomyopathy. (D) Non-specific electrocardiographic abnormalities, such as first-degree
atrio-ventricular block and prolonged QRS duration in a patient affected by chemotherapy-induced dilated cardiomyopathy. Notably, a long
QTc can be seen, which is associated with worse long-term prognosis.
of <30% and LBBB with a QRS duration of ≥150ms.65 A wider
QRS has also emerged as a predictor of ventricular arrhythmias63,67,68
and, more interestingly, has been independently associated with early
(<6 months) arrhythmic events.69
The impact of new-onset arrhythmias is also relevant for DCM
prognosis. Atrial fibrillation (both at baseline and development during
follow-up) has been associated with poor long-term survival and need
for heart transplantation in patients with DCM.9
Fragmentation of the QRS complex (i.e. the presence of notch-
ing of the QRS or an additional R wave) carries a higher risk for
major ventricular arrhythmias and major adverse cardiac events.68,70–73
More recently, low QRS amplitude and anterolateral TWI emerged
as independent predictors of major ventricular arrhythmias and SCD
in patients with DCM.5,28 Merlo et al.5 recently showed that specific
ECG features, including TWI in anterolateral leads, LVH (according to
Sokolow–Lyon criteria) and higher heart rates are predictors of heart
transplant and death.
Although many ECG features may underlie a propensity for poten-
tially fatal cardiac arrhythmias, none of these are included in the rec-
ommendations for ICD implantation in primary prevention, which are
still based on LV ejection fraction and NYHA class only.64
Clinical implications
A learned ECG interpretation is extremely valuable when approaching
patients with unexplained LV systolic dysfunction and/or LV dilatation.
A systematic approach to ECG interpretation may reveal features .
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. that point toward specific forms of DCM with implications in clini-
cal management. Certain ECG ‘red flags’ may suggest to look beyond
the echocardiogram and to request additional tests as CMR, Holter
monitoring and exercise tolerance test, avoiding an LV ejection
fraction-centred approach (Figure 4).
Gaps in evidence and future suggestions
Most studies on ECG in DCM are single-centre retrospective
studies. Despite the rapid increase in the understanding of the
genotype–phenotype correlations in DCM and the role of the ECG in
this context, the knowledge on the modifications of the ECG during
the natural history of the disease is still limited. As the definition of
DCM is based mainly on structural features as LV dilatation and systolic
dysfunction, clinical research has focused mainly on imaging tools such
as echocardiography and more recently CMR. Future studies should
include ECG data systematically in order to identify possible additional
roles of the ECG in the diagnosis and risk stratification of the disease.
Conclusions
The ECG is a cornerstone in the diagnosis and management
of cardiomyopathies. While traditionally the ECG was con-
sidered non-specific in DCM, a deeper understanding of the
genotype–phenotype correlations and of the complex aetiological
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Red flags at the electrocardiogram in patients presenting with unexplained left ventricular (LV) systolic dysfunction. AF,
atrial fibrillation; AV, atrio-ventricular; CRT, cardiac resynchronization therapy; DES, desmin; DMD, dystrophin; DSP, desmoplakin; EMD,
Emery–Dreifuss; FLNC, filamin C; LBBB, left bundle branch block; LMNA, lamin A/C; PLN, phospholamban; RBBB, right bundle branch block;
SCN5A, cardiac sodium channel type 5 𝛼-subunit; SVT, supraventricular tachycardia; TIC, tachycardia-induced cardiomyopathy; TWI, T-wave
inversion; VPB, ventricular premature beat.
background underlying a DCM phenotype, increasingly reveals
ECG patterns and ‘red flags’ that provide the opportunity to
early identify or suspect specific genetic and acquired forms. A
‘cardiomyopathy-oriented’ ECG interpretation in the setting of LV
or biventricular systolic dysfunction may suggest clinical scenarios
requiring a specific approach in terms of clinical management.
For example the finding of just a mild LV systolic dysfunction at
echocardiography in a young patient may wrongly reassure the
clinician. In fact, if this feature is combined with certain ECG
‘red flags’ such as AV blocks and/or AF, a laminopathy should be
excluded; if instead low voltages and TWI in the lateral leads are
found, a desmosomal disease should be suspected with major
implications not only for the patient but also for first-degree
family members who may potentially be at risk. A learned ECG
interpretation combined with a wise use of the most advanced
imaging techniques and genetic testing is extremely useful in the
approach to patients where clinical management is often complex,
despite continuous developments in cardiovascular medicine.
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